tirzepatide and long covid Obesity drug seen as effective for COVID, gets clinical trial Dr. Khan (@longcovidmd) speaks with

VitaStir patients using compounded tirzepatide should expect results in a similar range, though individual variation is enormous

For patients initiating tirzepatide, the following monitoring approach is recommended: Obtain baseline dilated eye examination before starting therapy, particularly in patients with known retinopathy Schedule follow-up ophthalmologic evaluation within 3 to 6 months of treatment initiation for patients with pre-existing retinopathy Maintain appropriate screening intervals (annual or every 1-2 years) for patients without baseline retinopathy based on glycemic control For pregnant women with preexisting diabetes, obtain an eye examination in the first trimester with close follow-up throughout pregnancy Coordinate care between primary care, endocrinology, and ophthalmology providers Patients should be instructed to seek immediate ophthalmologic evaluation (same-day or next-day) if they experience: Sudden vision loss or significant vision changes New floaters or flashing lights Curtain-like shadow across the visual field Persistent blurred vision not explained by refractive changes Healthcare providers should document baseline retinopathy status, communicate treatment plans with eye care specialists, and maintain awareness that optimal long-term glycemic controlachieved through medications like tirzepatideremains the most effective strategy for preventing vision-threatening diabetic eye disease

This dose should be maintained for at least four weeks to assess tolerance and initial therapeutic response before considering further dose escalation

Since responses can differ from person to person, the risks outlined here may not capture the full picture